People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Osteal Therapeutics, Inc. | — | Pharmaceuticals | Series C | $127.5M | $87.1M | 2023 |
| Tempo Therapeutics, Inc. | — | Biotechnology | Series B | $20.2M | $134.4M | 2024 |
Biren Mehta at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Biren Mehta on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Thompson | 1 | 10 |
| Renee Ryan | 1 | 6 |
| Douglas Kohrs | 1 | 4 |
| Rushu Luo | 1 | 3 |
| Dino Di Carlo | 1 | 2 |
| Steven Sands | 1 | 2 |
| Steven Richieri | 1 | 2 |
| David Cash | 1 | 2 |
| Noam Krantz | 1 | 2 |
| Jude Paganelli | 1 | 2 |
| Martin Sands | 1 | 2 |
| Sonal Patel | 1 | 1 |
| Robin Sitver | 1 | 1 |
| Westbrook Weaver | 1 | 1 |
| Richard Hancock | 1 | 1 |
| Brian De Beaubien | 1 | 1 |
| Donald Griffin | 1 | 1 |
| Judson Cooper | 1 | 1 |
| Erik Oros | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.